A therapeutic vaccine that reduces recurrent herpes simplex virus type 1 corneal disease

Investigative Ophthalmology and Visual Science

Volumn 39, Issue 7, 1998, Pages 1163-1170

  Nesburn, Anthony B ^a,b,d   Burke, Rae Lyn ^c   Gbiasi, Homayon ^a,b   Slanina, Susan M ^a   Wechsler, Steven L ^a,b  

^a BURNS AND ALLEN RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; GLYCOPROTEIN D; RECOMBINANT GLYCOPROTEIN D; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORNEA ULCER; DRUG EFFICACY; FEMALE; HERPES; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; NONHUMAN; PRIORITY JOURNAL; RABBIT; SUBCONJUNCTIVAL DRUG ADMINISTRATION; VACCINATION; VIRUS INFECTION; VIRUS SHEDDING;

EID: 0031862117     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Nesbum AB, ed. Report of the corneal diseuse panel: Vision research: A national plan 1983-1987. Vol 2, Part 3. St. Louis, MO: CV Mosby; 1983.
2. Corey L, Spear PG. Infections with herpes simplex viruses (1). N Engl J Med. 1986;314:686-691.
3. Corey L, Spear PG. Infections with herpes simplex viruses (2). N Engl J Med. 1986;314:749-757.
4. Ghiasi H, Bahri S, Nesbum AB, Wechsler SL. Protection against herpes simplex virus-induced eye disease after vaccination with seven individually expressed herpes simplex virus 1 glycoproteins. Invest Ophthalmol Vis Sci. 1995;36:1352-1360.
5. Ghiasi H, Nesburn AB, Wechsler SL. Vaccination with a cocktail of seven recombinantly expressed HSV-1 glycoproteins protects against ocular HSV-1 challenge more efficiently than vaccination with any individual glycoprotein. Vaccine. 1996;14:107-112.
6. Nesburn AB, Ghiasi H, Wechsler SL. Ocular safety and efficacy of an HSV-1 gD vaccine during primary and latent infection. Invest Ophthatmol Vis Sci. 1990;31:1497-1502.
7. Keadle TL, Laycock KA, Miller JK, et al. Efficacy of a recombinant glycoprotein D subunit vaccine on the development of primary and recurrent ocular infection with herpes simplex virus type 1 in mice. J Infect Dis. 1997;176:331-338.
8. Morrison LA, Knipe DM. Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1. Virology. 1996;220:402-413.
9. Heiligenhaus A, Wells PA, Foster CS. Immunisation against HSV-1 keratitis with a synthetic gD peptide. Eye. 1995;9:89-95.
10. Heiligenhaus A, Berra A, Dutt JE, Zhao TZ, Wells PA, Foster CS. T-cell-induced prevention of HSV-1 keratitis by immunization with the synthetic peptide of glycoprotein D. Ophthalmologe. 1994; 91:608-616.
11. Irie H, Shimeld C, Williams N, Hill T. Protection against ocular and cutaneous infection with herpes simplex virus type 1 by intragastric immunization with live virus. J Gen Virol. 1993;74:1357-1362.
12. Foster CS, Sandstrom IK, Wells PA, Thompson P, Daigle J, Opremcak EM. Immunomodulation of experimental murine herpes simplex keratitis: II. Glycoprotein D protection. Curr Eye Res. 1988; 7:1051-1061.
13. Inoue Y, Ohashi Y, Shimomura Y, et al. Herpes simplex virus glycoprotein D. Protective immunity against murine herpetic keratitis. Invest Ophthalmol Vis Sci. 1990;31:411-418.
14. Nesburn AB, Burke RL, Ghiasi H, Slanina S, Bahn S, Wechsler SL. Vaccine therapy for ocular herpes simplex virus (HSV) infection: periocular vaccination reduces spontaneous ocular HSV type 1 shedding in latently infected rabbits. J Virol. 1994;68:5084-5092.
15. Perng GC, Dunkel EC, Geary PA, et al. The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency. J Virol. 1994;68:8045-8055.
16. Perng GC, Slanina SM, Ghiasi H, Nesburn AB, Wechsler SL. A 371-nucleotide region between the herpes simplex virus type 1 (HSV-1) LAT promoter and the 2-kilobase LAT is not essential for efficient spontaneous reactivation of latent HSV-1. J Virol. 1996; 70:2014-2018.
17. Perng GC, Ghiasi H, Slanina SM, Nesburn AB, Wechsler SL. The spontaneous reactivation function of the herpes simplex virus type 1 LAT gene resides completely within the first 1.5 kilobases of the 8.3-kilobase primary transcript. J Virol. 1996;70:976-984.
18. Langenberg AG, Burke RL, Adair SF, et al. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity (corrected). Ann Intern Med. 1995;122:889-898. Published erratum appears in Ann Intern Med. 1995;123:395.
19. Straus SE, Wald A, Kost RG, et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoprotcins D and B: results of a placebo-controlled vaccine trial. J Infect Dis. 1997;176:1129-1134.
20. Walker J, Laycock K, Pepose J, Leib D. Postexposure vaccination with a virion host shutoff defective mutant reduces UV-B radiationinduced ocular herpes virus shedding in mice. Vaccine. 1998;16: 6-8.
21. Laycock KA, Brady RH, Lee SF, Osborne PA, Johnson EM, Pepose JS. The role of nerve growth factor in modulating herpes simplex virus reactivation in vivo. Graefes Arch Clin Exp Ophthalmol. 1994;232:421-425.